Optimal Design of Biomarker-Based Screening Strategies for Early Detection of Prostate Cancer
|
|
- Aron Ward
- 6 years ago
- Views:
Transcription
1 Optimal Design of Biomarker-Based Screening Strategies for Early Detection of Prostate Cancer Brian Denton Department of Industrial and Operations Engineering University of Michigan, Ann Arbor, MI October 13, 2014 Michigan Brian Denton Prostate Cancer Screening 1
2 Prostate Cancer Prostate cancer is the most common cancer among men: 60-80% of men will eventually develop prostate cancer 1 in 7 men will be diagnosed during his lifetime 1 in 36 men will die of prostate cancer Michigan Brian Denton Prostate Cancer Screening 2
3 Biomarker-Based Cancer Screening Physicians use biomarker tests to screen healthy men for asymptomatic, early-stage cancer Catching cancer at an early stage can increase a patient s chance of survival and decrease the cost of treatment Prostate-specific antigen (PSA) test is the biomarker that is most commonly used for prostate cancer screening Michigan Brian Denton Prostate Cancer Screening 3
4 New Biomarker Tests T2:ERG Urine test In late stage clinical validation PCA3 Urine test FDA approved for repeat biopsy More than a dozen other prostate cancer biomarkers have been discovered. Michigan Brian Denton Prostate Cancer Screening 4
5 Controversy Sophisticated new prostate cancer tests are coming to market that might supplement the unreliable PSA test, potentially saving tens of thousands of men each year from unnecessary biopsies, operations and radiation treatments. - The New York Times Pollack A (2013) New Prostate Cancer Tests Could Reduce False Alarms. New York Times. 26 March The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Rigau et. al. (2013) The Present and Future of Prostate Cancer Urine Biomarkers. Int J Mol Sci., 14(6): Michigan Brian Denton Prostate Cancer Screening 6
6 Harms and Benefits Longer life expectancy with early detection and treatment Unnecessary biopsies and overtreatment High costs of biomarker tests, biopsy and treatment Michigan Brian Denton Prostate Cancer Screening 7
7 Harms and Benefits Longer life expectancy with early detection and treatment Unnecessary biopsies and overtreatment High costs of biomarker tests, biopsy and treatment Conflicting guidelines for PSA screening American Urological Association (AUA, 2013) American Cancer Society (ACS, 2010) National Comprehensive Cancer Network (NCCN, 2010) U.S. Preventive Services Task Force (USPSTF, 2008, revised 2011, revised 2012,...) Michigan Brian Denton Prostate Cancer Screening 7
8 Research Questions Can optimization models help inform clinical screening decisions? Can biomarkers be used for minimally invasive early detection of prostate cancer? What factors influence the effectiveness of prostate cancer screening? Michigan Brian Denton Prostate Cancer Screening 8
9 Typical Screening Process Biopsy + Treatment Y PSA Test Result Biopsy? N Y Biopsy Result Biopsy - Y PSA Test? N PSA Test? N Epoch t Epoch t+1 Men 40 years and older receive routine annual PSA tests Physician (and patient) decides whether to refer for biopsy Michigan Brian Denton Prostate Cancer Screening 9
10 Typical Screening Process Biopsy + Treatment Y PSA Test Result Biopsy? N Y Biopsy Result Biopsy - Y PSA Test? N PSA Test? N Epoch t Epoch t+1 Michigan Brian Denton Prostate Cancer Screening 9
11 Partially Observable Markov Chain NC OC NC OC NC p t (C NC) C EP C EP C p t (T C) T M LN M LN p t (D C) M D D p t (D NC) D Markov transitions between prostate cancer states: No cancer (NC) Unobservable Cancer present but not detected (C) Unobservable Cancer detected (T) Treated immediately after detected Death (D) Prostate cancer and other cause mortality Michigan Brian Denton Prostate Cancer Screening 10
12 Partially Observable Markov Decision Process (POMDP) Objective: maximize expected benefits minus costs: Societal willingness to pay, β dollars/qaly Reward = β QALY Cost of Screening and Treament Three decisions at each decision epoch: Defer biomarker testing (DP) Defer biopsy (DB) Biopsy (B) Michigan Brian Denton Prostate Cancer Screening 11
13 POMDP Notation t: decision epochs every 6 months from age 40 to age 95 s t : health state at start of epoch t o t : biomarker observation at start of epoch t p t (s t+1 s t, a t ): transition probability between health states s t to s t+1 q t (o t s t ), s t S, o t O: probability of observing PSA level o t in health state s t in epoch t r t (s t, a t ): reward at epoch t Michigan Brian Denton Prostate Cancer Screening 12
14 Sequential Updating of Cancer Risk Biomarker test results are observed over time: The probability a patient is in a given health state at epoch t is estimated using the entire history of observations: Pr t+1 (s t+1 ) = q t+1 (o t+1 s t+1 ) p t (s t+1 s t, a t )Pr t (s t ) s t+1 S s t S q t+1 (o t+1 s t+1 ) p t (s t+1 s t, a t )Pr t (s t ) s t S Michigan Brian Denton Prostate Cancer Screening 13
15 Annual Rewards: Societal Perspective r t (NC, DP) = β r t (NC, DB) = β c p r t (NC, B) = β(1 µ) c b r t (C, DP) = β r t (C, DB) = β c p r t (C, B) = β(1 µ f ɛ) c b f c t f Biopsy detection rate µ Utility decrement of biopsy ɛ Annual utility decrement after treatment β Societal willingness to pay per QALY c p Cost of a PSA test c b Cost of a biopsy Cost of prostate cancer treatment c t Michigan Brian Denton Prostate Cancer Screening 14
16 Optimality Equations Decisions are based on risk of prostate cancer by selecting among the three possibilities: defer PSA test, PSA test, or biopsy v t (Pr t (C)) = max {v t (Pr t (C), DP), v t (Pr t (C), DB), v t (Pr t (C), B)} Properties: For any policy the sequence of Pr t (C) is a Markov process v t (Pr t (C)) is piecewise linear convex Michigan Brian Denton Prostate Cancer Screening 15
17 Optimality Equations Select among three actions: defer testing, PSA test only, or biopsy where v t (Pr t (C)) = max {v t (Pr t (C), DP), v t (Pr t (C), DB), R t (Pr t (C))}, t R t (Pr t (C)) = (1 Pr t (C)) R t (NC) + Pr t (C)((1 f ) R t (C) + f R t (T)) βµ c b Michigan Brian Denton Prostate Cancer Screening 16
18 Optimality Equations Select among three actions: defer testing, PSA test only, or biopsy where v t (Pr t (C)) = max {v t (Pr t (C), DP), v t (Pr t (C), DB), R t (Pr t (C))}, t R t (Pr t (C)) = (1 Pr t (C)) R t (NC) + Pr t (C)((1 f ) R t (C) + f R t (T)) βµ c b v t (Pr t (C), DB) = r t (Pr t (C), DB) + o t+1 O v t+1 (Pr t+1 (C))p t (o t+1 Pr t (C), DB) Michigan Brian Denton Prostate Cancer Screening 16
19 Optimality Equations Select among three actions: defer testing, PSA test only, or biopsy where v t (Pr t (C)) = max {v t (Pr t (C), DP), v t (Pr t (C), DB), R t (Pr t (C))}, t R t (Pr t (C)) = (1 Pr t (C)) R t (NC) + Pr t (C)((1 f ) R t (C) + f R t (T)) βµ c b v t (Pr t (C), DB) = r t (Pr t (C), DB) + o t+1 O v t+1 (Pr t+1 (C))p t (o t+1 Pr t (C), DB) v t (Pr t (C), DP) = r t (Pr t (C), DP) + v t+1 (Pr t+1 (C))p t (Pr t+1 (C) Pr t (C), DP) Michigan Brian Denton Prostate Cancer Screening 16
20 Model Analysis Proposition The incremental benefit of an additional PSA test in expected QALYs is non-negative. Theorem The optimal biopsy referral policy is of control-limit type such that { a W, if Prt (C) Pr t (C) t (Pr t (C)) = B, if Pr t (C) > Pr t (C). 1 Zhang, J., Denton, B.T., Balasubramanian, H., Inman, B., Shah, N., Optimization of Prostate Biopsy Decisions, MSOM, 14(4), , 2012 Michigan Brian Denton Prostate Cancer Screening 17
21 Model Analysis Theorem There exists a finite age, N, at which it is optimal to discontinue biopsy referral if and only if the following condition is satisfied: R N (T) R N (C) µ/f. Corollary If a t (Pr t(c)) = W, Pr t (C) [0, 1], t N, PSA screening should be discontinued. 1 Zhang, J., Denton, B.T., Balasubramanian, H., Inman, B., Shah, N., Optimization of Prostate Biopsy Decisions, MSOM, 14(4), , 2012 Michigan Brian Denton Prostate Cancer Screening 18
22 Sampling Based Solution Method Basic Idea: approximate the value function with a combination of inner and outer linearization subject to a fixed computing budget (d) A minimal α-vector set (e) A lower bound (f) An upper bound v v v 0 1 π 0 1 π 0 1 π Michigan Brian Denton Prostate Cancer Screening 19
23 Lower Bound Lt = arg min s.t. L t c L t W t x Π ( ) max w x max l x f t (x)dx w W t l L t LB heuristic: Step 1. Initialize L T as the true minimal α-vector set, L T. Set t = T 1. Sample belief point sets, N t, for t=1,..., T. Step 2. Using L t+1 find the dominating α-vector at all the belief points in N t and estimate a probability of dominance. Step 3. Select c vectors with highest probability. Let t = t 1. If t = 1 stop; otherwise return to Step 2. Michigan Brian Denton Prostate Cancer Screening 20
24 Upper Bound Ut = arg min s.t. U t Y t U t k, UB heuristic: x Π min g y [0,1], y Y min v g u [0,1], u U t (u)g u g u u = x, g u = 1 u U u U u U { }) v t (y)g y g y Y t y y = x, g y = 1 f t (x)dx y Y y Y Step 1. Compute the value functions at all the points in N T. Let t = T 1. Step 2. Estimate the value function for all belief points in N t using inner linearization for the value functions of all the points in N t+1. Step 3. Let t = t 1. If t = 1 stop; otherwise return to start of Step 2. Michigan Brian Denton Prostate Cancer Screening 21
25 Optimal PSA Screening Policies Probability of having PCa B DB DP From patient perspective ɛ = µ = Age Probability of having PCa B DB DP From societal perspective β = 50, 000 ɛ = µ = Age 1 Zhang, J., Denton, B.T., Balasubramanian, H., Inman, B., Shah, N., Optimization of PSA Screening Policies, Medical Decision Making, 32(2), , 2012 Michigan Brian Denton Prostate Cancer Screening 22
26 Screening Benefit from the Patient Perspective ɛ µ Benefit over no Benefit over Screening PSA screening traditional guideline stopping (QALYs/person) (QALYs/person) age > > > Table: Comparison of optimal screening vs. no screening and the traditional guideline for 40-year-old healthy men 1 Base case: annual incremental benefit of 293,000 QALYs for U.S. population Michigan Brian Denton Prostate Cancer Screening 23
27 Screening Benefit from the Societal Perspective β 100,000 50,000 25,000 costs Cost of the Cost of the Screening optimal policy traditional guideline stopping (U.S. $/person) (U.S. $/person) age 20% base case % % base case % % base case % Table: Sensitivity analysis of the total costs of the optimal policy and the traditional guideline for 40-year-old healthy men 1 Base case: annual cost saving of 166 million dollars for the U.S. population Michigan Brian Denton Prostate Cancer Screening 24
28 Sensitivity Analysis of Expected QALYs d t w t ε z t µ γ e t f b t Figure: Expected QALYs of 40 year old male with Pr 40 (C) = 0 Michigan Brian Denton Prostate Cancer Screening 25
29 Incorporating New Biomarker Tests T2:ERG Distinguishes between low and high grade cancers PCA3 FDA approved for use in combination with PSA Michigan Brian Denton Prostate Cancer Screening 26
30 Expanded Prostate Cancer Treatment Options Radical Prostatectomy Surgical removal of the prostate Appropriate when the cancer is contained in the prostate Active Surveillance Treatment option for patients with low-risk prostate cancer Delays and possibly avoids curative treatment until evidence of disease progression Michigan Brian Denton Prostate Cancer Screening 27
31 Partially Observable Markov Chain Depending on which core state the patient is in, we sample from the appropriate probability distribution for their biomarker results Michigan Brian Denton Prostate Cancer Screening 28
32 Multiple Biomarker-Based Screening Sequential biomarker threshold-based policies: Risk threshold based policies: Pr(PCa) = logit 1 ( β 0 + β 1 PSA + β 2 PCA3 + β 3 T2:ERG) Michigan Brian Denton Prostate Cancer Screening 29
33 Numerical Experiments No Screening, PSA threshold, PSA+PCA3 threshold, PSA + T2ERG threshold, PSA+PCA3+T2ERG Risk Score All combinations of biopsy thresholds for PSA, PCA3, T2ERG, increments of.05 for risk scores Screening frequency based on published schedules: Schedule Range of Screening Label Ages (yr) Interval (yr) Source S Ross et al. (2000) S Ross et al. (2000) S Ross et al. (2000), Andriole et al. (2009) S4 40,45 - Ross et al. (2000) S5 40,45 - Ross et al. (2000) S Heijnsdijk et al. (2012) S Heijnsdijk et al. (2012) S Heijnsdijk et al. (2012) S Heijnsdijk et al. (2012) S Heijnsdijk et al. (2012) S Heijnsdijk et al. (2012) Michigan Brian Denton Prostate Cancer Screening 30
34 Results: Public Health Perspective Michigan Brian Denton Prostate Cancer Screening 31
35 Results: Patient Perspective Michigan Brian Denton Prostate Cancer Screening 32
36 Conclusions Fast approximations for POMDPs for PCa screening can achieve near optimal solutions Combining multiple biomarkers can increase quality adjusted life years, reduce the probability of metastasis, and reduce the probability of receiving a biopsy Factors that most influence the effectiveness of prostate cancer screening are: accuracy of high grade cancer detection, other cause mortality, and cancer incidence Michigan Brian Denton Prostate Cancer Screening 33
37 Acknowledgments Christine Barnett, University of Michigan James Montie, MD, University of Michigan Todd Morgan, MD, University of Michigan Scott Tomlins, MD, PhD, University of Michigan Daniel Underwood, MSc, North Carolina State University John Wei, MD, University of Michigan Jingyu Zhang, PhD, Phillips Research This project is funded in part by the National Science Foundation through Grant Number: CMMI Brian Denton, Department of Industrial and Operations Engineering, University of Michigan Homepage: btdenton Michigan Brian Denton Prostate Cancer Screening 34
38 PSA Sampling Method PSA growth model developed by Gulati et al. (2010): where: log{y i (t)} = β 0i + β 1i t + β 2i (t t oi )I(t > t oi ) + ɛ, y i (t) is the PSA level for individual i at age t t = 0 corresponds to age 35 t oi is the age at onset of a preclinical tumor for individual i Individual intercepts and slopes are given by β ki N(µ k, σ 2 k ) for k = 0, 1, 2 R. Gulati, L. Inoue, J. Katcher, W. Hazelton, R. Etzioni. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics, 11(4): , Michigan Brian Denton Prostate Cancer Screening 35
39 Model Validation Statistic Model Estimate Literature Estimate Literature Source Overall prostate cancer (0.027, 0.029) Howlader et al. (2012) death rate Expected lifespan for (37.92, 38.14) 37.7 Elizabeth (2010) 40-year-old man (yr.) Overall diagnosis rate (0.104, 0.109) Howlader et al. (2012) Biopsy-detectable Age Prevalence Age Prevalence Haas et al. (2007) prostate cancer 50 8% 50 13% prevalence 60 19% 60 22% 70 33% 70 36% 80 49% 80 51% 89 62% 89 65% Michigan Brian Denton Prostate Cancer Screening 36
40 Experiments: Biopsy Thresholds PSA: {1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6.5} PCA3: {19, 25, 35, 55, 75} T2:ERG: {7, 10, 30, 50, 100} MiPS: {0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50} Michigan Brian Denton Prostate Cancer Screening 37
Using Markov Models to Estimate the Impact of New Prostate Cancer Biomarkers
Using Markov Models to Estimate the Impact of New Prostate Cancer Biomarkers Brian Denton, PhD Associate Professor Department of Industrial and Operations Engineering February 23, 2016 Industrial and Operations
More informationStochastic Models for Improving Screening and Surveillance Decisions for Prostate Cancer Care
Stochastic Models for Improving Screening and Surveillance Decisions for Prostate Cancer Care by Christine Barnett A dissertation submitted in partial fulfillment of the requirements for the degree of
More informationUsing Longitudinal Data to Build Natural History Models
Using Longitudinal Data to Build Natural History Models Lessons learned from modeling type 2 diabetes and prostate cancer INFORMS Healthcare Conference, Rotterdam, 2017 Brian Denton Department of Industrial
More informationManufacturing and Services Operations Management. Optimization of Prostate Biopsy Referral Decisions
Optimization of Prostate Biopsy Referral Decisions Journal: Manufacturing and Service Operations Management Manuscript ID: MSOM--0.R Manuscript Type: Special Issue - Healthcare Keywords: Health Care Management,
More informationOptimization of PSA Screening Policies: a Comparison of the Patient and Societal Perspectives
University of Massachusetts Amherst From the SelectedWorks of Hari Balasubramanian March, 2012 Optimization of PSA Screening Policies: a Comparison of the Patient and Societal Perspectives Jingyu Zhang
More informationProstate cancer is the most common solid tumor in American men and is screened for using prostate-specific
MANUFACTURING & SERVICE OPERATIONS MANAGEMENT Vol. 14, No. 4, Fall 2012, pp. 529 547 ISSN 1523-4614 (print) ISSN 1526-5498 (online) http://dx.doi.org/10.1287/msom.1120.0388 2012 INFORMS Optimization of
More informationMarkov Decision Processes for Chronic Diseases Lessons learned from modeling type 2 diabetes
Markov Decision Processes for Chronic Diseases Lessons learned from modeling type 2 diabetes Brian Denton Department of Industrial and Operations Engineering University of Michigan Agenda Models for study
More informationABSTRACT. Prostate cancer is the most common solid tumor that affects American men.
ABSTRACT ZHANG, JINGYU. Partially Observable Markov Decision Processes for Prostate Cancer Screening. (Under the direction of Dr. Brian T. Denton). Prostate cancer is the most common solid tumor that affects
More informationTITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening
TITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening RUNNING HEAD: Patient Heterogeneity in Prostate Cancer Screening June 17, 2016 Daniel J. Underwood,
More informationMarkov Decision Processes for Screening and Treatment of Chronic Diseases
Markov Decision Processes for Screening and Treatment of Chronic Diseases Lauren N. Steimle and Brian T. Denton Abstract In recent years, Markov decision processes (MDPs) and partially obserable Markov
More informationSimulation optimization of PSA-threshold based prostate cancer screening policies
Health Care Manag Sci DOI 10.1007/s10729-012-9195-x Simulation optimization of PSA-threshold based prostate cancer screening policies Daniel J. Underwood Jingyu Zhang Brian T. Denton Nilay D. Shah Brant
More informationTwo-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer
ORIGINAL ARTICLE Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer Christine L. Barnett, PhD, Scott A. Tomlins, MD, PhD, Daniel J. Underwood, PhD, John T.
More informationOptimal Design of Multiple Medication Guidelines for Type 2 Diabetes Patients
Optimal Design of Multiple Medication Guidelines for Type 2 Diabetes Patients Jennifer E. Mason PhD Student Edward P. Fitts Department of Industrial and Systems Engineering NC State University, Raleigh,
More informationEvaluating the Impact of Different Perspectives on the Optimal Start Time for Statins
Evaluating the Impact of Different Perspectives on the Optimal Start Time for Statins Jennifer E. Mason Edward P. Fitts Department of Industrial and Systems Engineering, NC State University, Raleigh, NC
More informationOptimization in Medicine
Optimization in Medicine INFORMS Healthcare Conference, Rotterdam, 2017 Brian Denton Department of Industrial and Operations Engineering University of Michigan Optimization in Medicine OR in Medicine Cancer
More informationc Copyright 2010 by Daniel J. Underwood All Rights Reserved
ABSTRACT UNDERWOOD, DANIEL J. Simulation Optimization of Prostate Cancer Screening Using a Parallel Genetic Algorithm. (Under the direction of Dr. Brian T. Denton.) We develop a parallel simulation-optimization
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationCost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer
Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer Christine L. Barnett*, Matthew S. Davenport, Jeffrey S. Montgomery, John T. Wei, James
More informationTranslating Evidence Into Policy The Case of Prostate Cancer Screening. Ruth Etzioni Fred Hutchinson Cancer Research Center
Translating Evidence Into Policy The Case of Prostate Cancer Screening Ruth Etzioni Fred Hutchinson Cancer Research Center Prostate Cancer Mortality in the US 2011 Prostate Cancer Mortality in the US 2011
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationProstate Cancer. Biomedical Engineering for Global Health. Lecture Fourteen. Early Detection. Prostate Cancer: Statistics
Biomedical Engineering for Global Health Lecture Fourteen Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United
More informationProstate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto
Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA
More informationOtis W. Brawley, MD, MACP, FASCO, FACE
Otis W. Brawley, MD, MACP, FASCO, FACE Chief Medical and Scientific Officer American Cancer Society Professor of Hematology, Medical Oncology, Medicine and Epidemiology Emory University Atlanta, Georgia
More informationINFERRING PROSTATE CANCER NATURAL HISTORY IN AFRICAN AMERICAN MEN IMPLICATIONS FOR SCREENING
INFERRING PROSTATE CANCER NATURAL HISTORY IN AFRICAN AMERICAN MEN IMPLICATIONS FOR SCREENING RUTH ETZIONI FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE, WASHINGTON RETZIONI@FREDHUTCH.ORG EVIDENCE-BASED
More informationActive Surveillance (AS) is an expectant management. Health Services Research
Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer Health Services Research Jianyu Liu, Paul R. Womble, Selin Merdan, David C. Miller, James E. Montie, Brian T. Denton on
More informationOverdiagnosis Issues in Population-based Cancer Screening
OVERDIAGNOSIS The Balance of Benefit, Harm, and Cost of PSA Screening Grace Hui-Ming Wu, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Sam Li-Sheng Chen, Jean Chin-Yuan, Fann, Tony Hsiu-Hsi Chen 2018-09-11
More informationProjecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer
Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer Jeanette K. Birnbaum 1, Ziding Feng 2,3,4, Roman Gulati 3, Jing Fan 4, Yair Lotan, 5 John T. Wei
More informationPROSTATE CANCER Amit Gupta MD MPH
PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment
More informationOptimization and Machine Learning Methods for Diagnostic Testing of Prostate Cancer
Optimization and Machine Learning Methods for Diagnostic Testing of Prostate Cancer by Selin Merdan A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
More informationShould A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests?
Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Hanan Goldberg, MD Princess Margaret Cancer Centre, UHN, Sunnybrook Health science Centre, University of Toronto, Toronto,
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationThe balance of harms and benefits of screening for prostate cancer: the apples and oranges problem solved
The balance of harms and benefits of screening for prostate cancer: the apples and oranges problem solved Harold C. Sox, MD, MACP The Patient-Centered Outcomes Research Institute April 2,2016 Declarations
More informationProstate Cancer Screening. Eric Shreve, MD Bend Urology Associates
Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationCancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies
8 ACOFP 55th Annual Convention & Scientific Seminars Cancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies Anthony
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Introduction #2: DIAGNOSTIC MEDICINE PROSTATE The prostate is part of a man s reproductive system. It is a gland surrounding the neck of the
More informationElectronic Health Record Analytics: The Case of Optimal Diabetes Screening
Electronic Health Record Analytics: The Case of Optimal Diabetes Screening Michael Hahsler 1, Farzad Kamalzadeh 1 Vishal Ahuja 1, and Michael Bowen 2 1 Southern Methodist University 2 UT Southwestern Medical
More informationActive surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationBAYESIAN JOINT LONGITUDINAL-DISCRETE TIME SURVIVAL MODELS: EVALUATING BIOPSY PROTOCOLS IN ACTIVE-SURVEILLANCE STUDIES
BAYESIAN JOINT LONGITUDINAL-DISCRETE TIME SURVIVAL MODELS: EVALUATING BIOPSY PROTOCOLS IN ACTIVE-SURVEILLANCE STUDIES Lurdes Y. T. Inoue, PhD Professor Department of Biostatistics University of Washington
More informationPSA testing in New Zealand general practice
PSA testing in New Zealand general practice Ross Lawrenson, Charis Brown, Fraser Hodgson. On behalf of the Midland Prostate Cancer Study Group Academic Steering Goup: Zuzana Obertova, Helen Conaglen, John
More informationPSA test. PSA testing is not usually recommended for asymptomatic men with < 10 years life expectancy Before having a PSA test men should not have:
PSA Debate PSA1 PSA2 PSA test PSA testing is not usually recommended for asymptomatic men with < 10 years life expectancy Before having a PSA test men should not have: had a DRE in the previous week. an
More informationSommerakademie Munich, June
Active surveillance: Shrinking the grey zone Sommerakademie Munich, June 30 2016 Active surveillance Overview of 20 year history Laurence Klotz, MD, CM Professor of Surgery Sunnybrook Heatlh Sciences Centre
More informationActive Surveillance for Intermediate Risk Prostate Cancer
Active Surveillance for Intermediate Risk Prostate Cancer Eric Wallen, M.D., FACS Professor Department of Urology The University of North Carolina at Chapel Hill Disclosures: None Objectives Understand
More informationPCA MORTALITY VS TREATMENTS
PCA MORTALITY VS TREATMENTS Terrence P McGarty White Paper No 145 July, 2017 In a recent NEJM paper the authors argue that there is no material difference between a prostatectomy and just "observation"
More informationOverview. What is Cancer? Prostate Cancer 3/2/2014. Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014
Prostate Cancer Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014 Overview Start with the basics: Definition of cancer Most common cancers in men Prostate, lung, and colon cancers Cancer
More informationThe 4Kscore A Precision Test for Risk of Aggressive Prostate Cancer. Reduce Unnecessary Invasive Procedures And Healthcare Costs
The 4Kscore A Precision Test for Risk of Aggressive Prostate Cancer Reduce Unnecessary Invasive Procedures And Healthcare Costs PSA Lacks Specificity for Aggressive Prostate Cancer Abnormal PSA leads to
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationABSTRACT. MASON, JENNIFER E. Optimal Timing of Statin Initiation for Patients with Type 2 Diabetes. (Under the direction of Dr. Brian Denton).
ABSTRACT MASON, JENNIFER E. Optimal Timing of Statin Initiation for Patients with Type 2 Diabetes. (Under the direction of Dr. Brian Denton). HMG Co-A reductase inhibitors (statins) are an important part
More informationSequential Decision Making
Sequential Decision Making Sequential decisions Many (most) real world problems cannot be solved with a single action. Need a longer horizon Ex: Sequential decision problems We start at START and want
More informationModule Overview. What is a Marker? Part 1 Overview
SISCR Module 7 Part I: Introduction Basic Concepts for Binary Classification Tools and Continuous Biomarkers Kathleen Kerr, Ph.D. Associate Professor Department of Biostatistics University of Washington
More informationAnn Intern Med. 2012;156(5):
Lung Cancer Screening Update Doug Arenberg, M.D. University of Michigan Outline Screening; Some simple but necessary truths Do people benefit from screening? What are the harms (and are they outweighed
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationScreening for Prostate Cancer US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationSetting The setting was secondary care. The economic study was conducted in the USA.
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis Elkin E B, Weinstein K C, Winer E P, Kuntz K M, Schnitt S J, Weeks J C Record Status This is a critical
More informationDebate: Genetics and Genomics should be used ONLY for re-biopsy
Debate: Genetics and Genomics should be used ONLY for re-biopsy Larry Goldenberg, CM, OBC, MD, FRCSC Professor, UBC Dept of Urologic Sciences Director of Development and Supportive Care, Vancouver Prostate
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationA Decision Analysis to Assess the Value of Prostate Cancer Screening:
A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus from Prostate Cancer Specific Mortality to Distant Metastasis Free Survival Arie Pablo Dosoretz, Nataniel H. Lester-Coll,
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationShared Decision Making in Breast and Prostate Cancer Screening. An Update and a Patient-Centered Approach. Sharon K. Hull, MD, MPH July, 2017
Shared Decision Making in Breast and Prostate Cancer Screening An Update and a Patient-Centered Approach Sharon K. Hull, MD, MPH July, 2017 Overview Epidemiology of Breast and Prostate Cancer Controversies
More informationSorveglianza Attiva update
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationA PARALLEL MICROSIMULATION PACKAGE FOR MODELLING CANCER SCREENING POLICIES
A PARALLEL MICROSIMULATION PACKAGE FOR MODELLING CANCER SCREENING POLICIES escience, 2016-10-26, Baltimore Andreas Karlsson andreas.a.karlsson@ki.se Co-authors: Niten Olofsson, Erwin Laure & Mark Clements
More informationSISCR Module 7 Part I: Introduction Basic Concepts for Binary Biomarkers (Classifiers) and Continuous Biomarkers
SISCR Module 7 Part I: Introduction Basic Concepts for Binary Biomarkers (Classifiers) and Continuous Biomarkers Kathleen Kerr, Ph.D. Associate Professor Department of Biostatistics University of Washington
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationMathematical Modeling for the Tumor Growth in the Bladder
IJISET - International Journal of Innovative Science, Engineering & Technology, Vol. 2 Issue 5, May 25. Mathematical Modeling for the Tumor Growth in the Bladder L. N. M. Tawfiq & S. A. Abdul-Jabbar Department
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationThe cost-effectiveness of expanded testing for primary HIV infection Coco A
The cost-effectiveness of expanded testing for primary HIV infection Coco A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract
More informationHarms and Benefits of Prostate Cancer Screening. and Active Surveillance
Harms and Benefits of Prostate Cancer Screening and Active Surveillance Gunstige en ongunstige effecten van het vroeg opsporing van prostaat kanker en actief opwachten Tiago M. C. D. Marques Harms and
More information3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD
PROSTATE CANCER IN 2018 Rahul Mehan, MD East Valley Urology Center 6116 E Arbor Ave, Bldg 2, Suite 108 Mesa, AZ 85206 rmehan@evucenter.com www.evucenter.com Snapchat: Dr.NoodleKing OBJECTIVE Offer interactive
More informationData-Driven Management of Post-Transplant Medications: An APOMDP Approach
Data-Driven Management of Post-Transplant Medications: An APOMDP Approach Alireza Boloori Industrial Engineering, School of Computing, Informatics and Decision Systems Engineering, Arizona State University,
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationC. Stephen Farmer, II MD Urology Associates
C. Stephen Farmer, II MD Urology Associates Benign Prostate Hypertrophy Benign Prostate Hypertrophy Symptoms Hesitancy Intermittency Nocturia Post-void dribbling Dysuria Urgency Frequency Hematuria Benign
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationSetting The setting was primary care. The economic study was conducted in the USA.
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Zeliadt S B, Etzioni R D, Penson D F, Thompson I M, Ramsey S D Record Status This is a critical abstract of
More informationThe Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017
The Evolving Role of PSA for Prostate Cancer Adele Marie Caruso, DNP, CRNP Adult Nurse Practitioner Perelman School of Medicine at the University of Pennsylvania November 4, 2017 The Evolving Role of PSA
More informationDESIGNING PERSONALIZED TREATMENT: AN APPLICATION TO ANTICOAGULATION THERAPY
DESIGNING PERSONALIZED TREATMENT: AN APPLICATION TO ANTICOAGULATION THERAPY by Rouba Ibrahim UCL School of Management, University College London, London, UK rouba.ibrahim@ucl.ac.uk, Tel: (44)20-76793278
More information16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -
Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationOsher Mini Medical School for the Public
Osher Mini Medical School for the Public Education Research Patient care Education Practice Basic science research First human studies Research Patient care Clinical studies Lifetime risk Prostate
More informationData-Driven Management of Post-Transplant Medications: An APOMDP Approach
Data-Driven Management of Post-Transplant Medications: An APOMDP Approach Alireza Boloori Industrial Engineering, School of Computing, Informatics and Decision Systems Engineering, Arizona State University,
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationSHARED DECISION MAKING FOR PROSTATE CANCER SCREENING
SHARED DECISION MAKING FOR PROSTATE CANCER SCREENING 16 TH A N N U A L M A S S A C H U S E T T S P R O S T A T E C A N C E R S Y M P O S I U M Mary McNaughton-Collins, MD, MPH Foundation Medical Director
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationPhase II Design. Kim N. Chi NCIC/NCIC-CTG NEW INVESTIGATORS CLINICAL TRIALS COURSE
Phase II Design Kim N. Chi NCIC/NCIC-CTG NEW INVESTIGATORS CLINICAL TRIALS COURSE Phase II Study Results Phase II Study Results Agenda Objectives of phase II trials Endpoints of phase II trials Statistical
More information4.5% 4.0% 3.5% 3.0% 2.5% 2.0% 1.5% 1.0% 0.5% 0.0% < >80 Current Age (Yrs)
Biomedical Engineering for Global Health Lecture Twelve Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United States:
More informationYour Guide to Prostate Cancer
Your Guide to Prostate Cancer If you face a diagnosis of prostate cancer, what s next? We can help. A prostate cancer diagnosis can be overwhelming. The good news is that while prostate cancer can be serious,
More informationPROSTATE CANCER: Meeting a Community Need
outcomes REPORT 2017 PROSTATE CANCER: Meeting a Community Need 1 in 6 men will be diagnosed with prostate cancer in their lifetime. 1 southnassau.org/cancer outcomes REPORT 2017 Within the primary service
More information